Brian McNamee - Amgen Insider

AMGN -- USA Stock  

USD 186.19  0.20  0.11%

Executive Vice President - Full Potential Initiatives

Mr. Brian M. McNamee is the Executive Vice President Full Potential Initiatives of Amgen Inc. Mr. McNamee joined the Company in June 2001 as Senior Vice President, Human Resources. From November 1999 to June 2001, Mr. McNamee served as Vice President of Human Resources at Dell Computer Corporationration From 1998 to 1999, Mr. McNamee served as Senior Vice President, Human Resources for the National Broadcasting Corporationrationration, a division of the GE. From July 1988 to November 1999, Mr. McNamee held human resources positions at GE.
Age: 59  President Since 2013      

Brian McNamee Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Jan LundbergEli Lilly and Company
Michael RosenblattMerck Co
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
Andrew LaneAbbott Laboratories
Robert StewartAllergan plc
Paul NavarreAllergan plc
Ashley WatsonMerck Co
Sanat ChattopadhyayMerck Co
Maria CroweEli Lilly and Company
John HertiaBio Rad Laboratories
Jared WatkinAbbott Laboratories
Francis CussBristol Myers Squibb Company
Louis SchmuklerBristol Myers Squibb Company
Annette TumoloBio Rad Laboratories
Stephen FussellAbbott Laboratories
Willie DeeseMerck Co
Antonio PeraEndo International plc
Darren CarrollEli Lilly and Company
Matthew MalettaEndo International plc
Joshua SmileyEli Lilly and Company
Timothy ErnstBio Rad Laboratories

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Current Sentiment - AMGN

Amgen Investor Sentiment
Majority of Macroaxis users are presently bullish on Amgen. What is your sentiment towards investing in Amgen? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.